Trial Profile
An Observation, Open Label Study of Alpharadin (Radium 223) in Patients With Castrate Resistant Prostate Cancer Bone Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 22 Mar 2021 Results of exosomal transcriptome analysis from preclinical models and plasma of 25 patients published in the Clinical Cancer Research
- 12 Nov 2020 Status changed from active, no longer recruiting to completed.
- 20 Dec 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Jun 2020.